Meng An Bought 5.8% More Shares In Consun Pharmaceutical Group
Meng An Bought 5.8% More Shares In Consun Pharmaceutical Group
Those following along with Consun Pharmaceutical Group Limited (HKG:1681) will no doubt be intrigued by the recent purchase of shares by Meng An, CEO & Executive Chairman of the company, who spent a stonking HK$5.4m on stock at an average price of HK$5.64. There's no denying a buy of that magnitude suggests conviction in a brighter future, although we do note that proportionally it only increased their holding by 5.8%.
关注康臣药业集团有限公司(HKG:1681)的人无疑会对公司的首席执行官兼执行主席孟安最近购买股票的行为感到好奇,他花了540万港元以平均5.64港元的价格购买了一大笔股票。毫无疑问,这种规模的买入行为表明对更加光明的未来的信心,尽管我们注意到,从比例上看,这仅增加了他们持有的股份5.8%。
The Last 12 Months Of Insider Transactions At Consun Pharmaceutical Group
在康臣药业集团过去12个月的内部交易中,有人进行了股票买卖。
The insider, Yubao An, made the biggest insider sale in the last 12 months. That single transaction was for HK$62m worth of shares at a price of HK$6.70 each. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The good news is that this large sale was at well above current price of HK$5.67. So it is hard to draw any strong conclusion from it.
在过去12个月的内部交易中,内部人员鞠葆进行了最大规模的内部人员卖出。 这单笔交易金额为6200万港元,每股售价为6.70港元。尽管内部人员的卖出是一个负面因素,对我们来说,如果股票以更低价格出售,将更加负面。 好消息是,这笔大额销售的价格远高于目前的5.67港元。 因此,很难从中得出任何明确的结论。
Happily, we note that in the last year insiders paid HK$22m for 4.14m shares. But insiders sold 10.51m shares worth HK$70m. All up, insiders sold more shares in Consun Pharmaceutical Group than they bought, over the last year. The sellers received a price of around CN¥6.68, on average. We are not joyful about insider selling. But the selling was at much higher prices than the current share price (HK$5.67), so it probably doesn't tell us a lot about the value on offer today. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
令人高兴的是,我们发现在过去一年内,内部人员支付了2200万港元购买414万股股票。 但内部人员卖出了价值7000万港元的1051万股。 总的来说,内部人员在康臣药业集团卖出的股票数量多于购买的数量。 卖家平均得到了约6.68人民币的价格。 我们对内部人员的卖出行为并不感到高兴。 但这些卖出行为的价格远高于当前股价(5.67港元),因此可能并不能反映出当下的价值。 下图显示了过去一年内部交易(公司和个人)的情况。 如果您单击图表,您可以查看所有的个人交易,包括股价、个人和日期!
If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.
如果您和我一样,您就不会错过这个免费的小盘股票列表,这些股票不仅被内部人士购买,而且估值也很有吸引力。
Does Consun Pharmaceutical Group Boast High Insider Ownership?
康济药业集团是否拥有高比例内部持股?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. Consun Pharmaceutical Group insiders own 45% of the company, currently worth about HK$2.1b based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
另一种测试公司领导人和其他股东之间对齐程度的方法是查看他们拥有多少股份。如果内部人员拥有大量股份,我认为这是一个好迹象。康济药业集团内部人员拥有公司45%的股份,根据最近的股价,目前价值约21亿港元。我很喜欢看到这种程度的内部持股,因为它增加了管理层考虑股东最佳利益的可能性。
So What Does This Data Suggest About Consun Pharmaceutical Group Insiders?
那么,这些数据对康济药业集团内部人员有何意义?
The recent insider purchases are heartening. On the other hand the transaction history, over the last year, isn't so positive. The recent buying by some insiders , along with high insider ownership, suggest that Consun Pharmaceutical Group insiders are fairly aligned, and optimistic. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Case in point: We've spotted 2 warning signs for Consun Pharmaceutical Group you should be aware of.
最近的内部购买是令人鼓舞的。另一方面,过去一年的交易历史并不乐观。一些内部人员最近的购买行为,以及高比例内部持股,表明康济药业集团内部人员的利益基本一致,并且持乐观态度。因此,了解内部人员在买卖方面的行为对于了解一家特定公司面临的风险也是有帮助的。具体例子:我们发现了康济药业集团存在两个警示信号,您应该注意。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
当然,您可能会在其他地方找到一项出色的投资。因此,请查看此免费的有趣公司列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
对于本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置,但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。